% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • biglabowski99 biglabowski99 Apr 27, 2013 11:20 AM Flag

    Role of Hdac Inhibitors in Patients with Relapsed Refractory Multiple Myeloma

    CUDC-907 will unlock value for cris in the next few months. look for more data on tues and wed earnings/investor conf call this week!!!!!!

    ABSTRACT Clinical outcomes for patients with multiple myeloma (MM) have improved substantially since the introduction of novel agents, including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide. However, most patients with MM eventually relapse and prognosis remains poor among patients with relapsed and/or refractory disease. Combination therapy using agents with different mechanisms of action is emerging as an attractive treatment approach in oncology to increase efficacy and/or overcome resistance to standard treatment regimens. This review discusses unmet needs in the treatment of MM and the development of histone deacetylase inhibitors as a treatment modality for MM

2.640.00(0.00%)Oct 27 4:00 PMEDT